Equities research analysts forecast that Cytosorbents Corp (NASDAQ:CTSO) will announce earnings per share (EPS) of ($0.13) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Cytosorbents’ earnings, with the lowest EPS estimate coming in at ($0.15) and the highest estimate coming in at ($0.11). Cytosorbents posted earnings of ($0.04) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 225%. The firm is expected to issue its next earnings results on Monday, August 6th.
On average, analysts expect that Cytosorbents will report full-year earnings of ($0.46) per share for the current year, with EPS estimates ranging from ($0.57) to ($0.37). For the next financial year, analysts anticipate that the company will post earnings of ($0.32) per share, with EPS estimates ranging from ($0.56) to ($0.11). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Cytosorbents.
Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings data on Tuesday, May 8th. The medical research company reported ($0.10) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.03. The company had revenue of $4.93 million for the quarter, compared to analysts’ expectations of $4.56 million. Cytosorbents had a negative net margin of 56.06% and a negative return on equity of 88.39%.
CTSO has been the topic of several research analyst reports. Maxim Group set a $13.00 price objective on shares of Cytosorbents and gave the stock a “buy” rating in a research report on Tuesday, May 15th. BidaskClub raised Cytosorbents from a “hold” rating to a “buy” rating in a research note on Thursday, May 17th. Cowen set a $9.00 target price on Cytosorbents and gave the stock a “buy” rating in a research note on Thursday, March 8th. ValuEngine raised Cytosorbents from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of Cytosorbents in a research note on Wednesday, May 9th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $11.25.
Shares of Cytosorbents remained flat at $$11.00 during trading on Friday, MarketBeat.com reports. 3,158,962 shares of the company traded hands, compared to its average volume of 250,690. The company has a debt-to-equity ratio of 0.68, a quick ratio of 5.99 and a current ratio of 6.16. The company has a market capitalization of $325.84 million, a PE ratio of -34.38 and a beta of 0.03. Cytosorbents has a one year low of $4.00 and a one year high of $12.35.
In other news, COO Vincent Capponi sold 7,154 shares of the stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $9.00, for a total transaction of $64,386.00. Following the completion of the sale, the chief operating officer now owns 321,551 shares of the company’s stock, valued at $2,893,959. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Kathleen P. Bloch sold 10,000 shares of the stock in a transaction that occurred on Monday, May 14th. The shares were sold at an average price of $8.50, for a total value of $85,000.00. Following the sale, the chief financial officer now directly owns 263,304 shares of the company’s stock, valued at approximately $2,238,084. The disclosure for this sale can be found here. In the last ninety days, insiders sold 77,674 shares of company stock valued at $781,976. 6.90% of the stock is owned by insiders.
Several large investors have recently added to or reduced their stakes in the company. Millennium Management LLC boosted its stake in shares of Cytosorbents by 134.4% during the first quarter. Millennium Management LLC now owns 384,330 shares of the medical research company’s stock valued at $2,710,000 after purchasing an additional 220,353 shares during the period. B. Riley Financial Inc. purchased a new stake in shares of Cytosorbents during the fourth quarter valued at approximately $992,000. Raymond James & Associates boosted its stake in shares of Cytosorbents by 100.0% during the fourth quarter. Raymond James & Associates now owns 100,000 shares of the medical research company’s stock valued at $650,000 after purchasing an additional 50,000 shares during the period. PEAK6 Investments L.P. boosted its stake in shares of Cytosorbents by 13.7% during the fourth quarter. PEAK6 Investments L.P. now owns 99,744 shares of the medical research company’s stock valued at $648,000 after purchasing an additional 12,022 shares during the period. Finally, BlueCrest Capital Management Ltd purchased a new stake in shares of Cytosorbents during the fourth quarter valued at approximately $396,000. 13.07% of the stock is owned by hedge funds and other institutional investors.
Cytosorbents Company Profile
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.